Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    24050512 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy
Condition: Helicobacter Infections
Interventions: Drug: esomeprazole;   Drug: tripotassium dicitrate bismuthate;   Drug: metronidazole;   Drug: tetracycline;   Drug: moxifloxacin;   Drug: amoxicillin

Indicates status has not been verified in more than two years